Review Article **ISSN: 3139-3683**

JOURNAL OF HEALTH SYNAPSE (JHS)
Peer Reviewed Refereed Open Access International Multidisciplinary Journal
Publisher: *Scientistic Era Private Limited*
Journal Hompage: *https://healthsynapse.org*

Integrative Ayurvedic Approaches in Cancer Supportive Care: A Review of Mechanistic Evidence, Clinical Outcomes, and Future Directions

Dr. Sonam Chauhan[a*], Dr. Sanjay Kumar Tiwari[b], Dr. Prachi Khandelwal[a], Dr. Himani Sharma[c], Dr. Shweta Bisht[d], Dr. Priya Goel[a]

[a]*Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.*
[b]*Department of Kayachikitsa, Bhartiya Ayurvedic Medical College, Gajraula, Amroha, Uttar Pradesh, India.*
[c]*Department of Shalakya Tantra, Sanjeevani Ayurvedic Medical College, Gajraula, Amroha, Uttar Pradesh, India.*
[d]*Department of Kayachikitsa, Dev Bhoomi Medical College of Ayurveda and Hospital, Dehradun, Uttrakhand, India.*

ARTICLE INFO

KEYWORDS:
Ayurveda; integrative oncology; cancer supportive care; Rasayana; Panchakarma; immunomodulation; Arbuda; herbal oncology; quality of life; chemoprevention

ARTICLE HISTORY
Received Date: 15 April 2026
Revised Date: 28April 2026
Accepted Date: 29 May 2026
Published Date: 30 June 2026

CITATION
Chauhan. S., 2026. Integrative Ayurvedic Approaches in Cancer Supportive Care: A Review of Mechanistic Evidence, Clinical Outcomes, and Future Directions. *Journal of Health Synapse (JHS), 1(2), 26-37. https://doi.org/*

A B S T R A C T

Background: Despite remarkable advances in surgical techniques, systemic chemotherapy, targeted agents, and immunotherapeutics, cancer continues to impose a devastating global burden - not merely through mortality, but through the profound erosion of patient quality of life that treatment itself often causes. Ayurveda, codified more than two millennia ago in the Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam, contains within its classical texts sophisticated descriptions of neoplastic disease (Arbuda, Granthi) alongside multi-modal management strategies encompassing pharmacology, detoxification, and dietetics. Over the past two decades, laboratory and clinical investigators have begun translating this classical knowledge into contemporary mechanistic terms, yielding a body of evidence that warrants serious scholarly attention.
Objective: To conduct a critical narrative synthesis of available mechanistic, preclinical, and clinical literature on Ayurvedic interventions in the supportive management of cancer, with particular attention to immune reconstitution, attenuation of treatment-related toxicity, and patient-reported quality-of-life outcomes.
Methods: Peer-reviewed literature published between January 2000 and December 2024 was retrieved from PubMed/MEDLINE, Scopus, Web of Science, and the AYUSH Research Portal. Boolean search strategies combined MeSH and free-text terms including: Ayurveda, integrative oncology, cancer supportive care, Rasayana, Panchakarma, immunomodulation, chemoprevention, Withania somnifera, Tinospora cordifolia, Curcuma longa, Triphala, and oral mucositis. Studies were included if they reported outcomes relevant to cancer symptom burden, treatment toxicity, or quality of life in human subjects or documented anti-cancer mechanisms in validated cell or animal models.
Conclusions: The reviewed evidence supports a clinically meaningful role for select Ayurvedic interventions - principally Rasayana herbs (Withania somnifera, Tinospora cordifolia, Emblica officinalis), classical polyherbal formulations (Triphala, Kanchnar Guggulu), and Panchakarma-based detoxification protocols - as adjuncts to conventional oncology. Documented benefits include mitigation of cancer-related fatigue, chemotherapy-induced nausea, radiation-induced oral mucositis, and myelosuppression. Methodological rigour, preparation standardisation, and pharmacokinetic characterisation remain areas requiring urgent attention before definitive clinical recommendations can be made.

I. Introduction

The global burden of cancer shows no signs of abating. GLOBOCAN 2022 estimated 20 million new diagnoses

and 9.7 million cancer-related deaths in a single year, with projections indicating a further 77% rise in incidence by 2050 if current trends persist.1 While therapeutic advances - including checkpoint immunotherapy, precision-targeted agents, and stereotactic radiotherapy - have meaningfully extended median survival across several tumour types, their capacity to improve the lived experience of cancer is often limited. Treatment-related fatigue, peripheral neuropathy, myelosuppression, mucositis, nausea, and psychological morbidity collectively constitute a quality-of-life crisis that conventional supportive care frequently fails to fully address.2

Within this clinical and humanistic gap, integrative oncology has emerged as a rigorous, evidence-seeking discipline - one that asks not whether ancient therapeutics are philosophically interesting, but whether they demonstrably benefit patients when subjected to the scrutiny of modern scientific methodology.2,21,24 Ayurveda, India's classical medical system, presents a particularly compelling case for integrative investigation. Its foundational texts - the Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam - contain descriptions of neoplastic disease (Arbuda, Granthi) and their management that, while articulated in the vocabulary of Tridosha physiology, encode clinical observations accumulated over centuries.3 Crucially, these texts prescribe not isolated botanicals but comprehensive multi-modal programmes integrating pharmacology, detoxification, dietetics, and lifestyle regulation - an approach that resonates with the systems-biology understanding of cancer as a disease of multiple disrupted pathways rather than a single molecular lesion.

The pharmacological investigation of Ayurvedic plants has intensified substantially over the past two decades. Bioactive constituents isolated from Rasayana (rejuvenating) herbs - withanolides, curcuminoids, tinosporin, boswellic acids, and emblicanins, among others - have been characterised at molecular level across multiple oncologically relevant targets.5,6,9,23,25-27 This review draws together the preclinical mechanistic evidence, emerging clinical data, and unresolved challenges that collectively define the current state of integrative Ayurvedic oncology. It is offered not as advocacy for one therapeutic tradition over another, but as a scholarly synthesis intended to assist clinicians, researchers, and policymakers in calibrating the place of Ayurvedic intervention within evidence-based cancer supportive care.

2. Classical Ayurvedic Conceptualisation of Neoplastic Disease

2.1 Arbuda, Granthi, and the Pathogenesis of Abnormal Growth

Classical Ayurvedic nosology distinguishes between Granthi - a smaller, benign, cystic swelling arising from the local vitiation of two doshas - and Arbuda, a larger, deeper, slowly expanding mass involving the vitiation of all three doshas together with derangement of Rakta (haematopoietic tissue), Mamsa (muscular parenchyma), and Meda (adipose stroma).3,4 The Sushruta Samhita provides a six-category classification of Arbuda based on doshic predominance - Vataja, Pittaja, Kaphaja, Raktaja (haematogenous), Mamsaja (soft tissue), and Medaja (lipomatous) - an organisational scheme that bears a non-trivial morphological correspondence to modern histopathological classification.4

Mechanistically, Ayurvedic pathogenesis situates the origin of Arbuda within a cascade initiated by sustained impairment of Agni (the transformative metabolic intelligence operating at cellular and organ levels) leading to the generation and systemic deposition of Ama - a heterogeneous category of incompletely processed, biologically reactive material. Ama produces Srotorodha (obstruction of anatomical and functional channels), precipitates chronic Doshic vitiation, and ultimately undermines Ojas - the immunological and vitalistic resource that in contemporary terms maps onto innate and adaptive immune competence, mitochondrial reserve, and neuroendocrine resilience.3,21,23 The resonance between this pathophysiological narrative and contemporary science's appreciation of the tumour microenvironment - characterised by chronic low-grade inflammation, metabolic reprogramming, immune checkpoint dysregulation, and progressive tissue depletion - is neither coincidental nor merely metaphorical; it reflects sophisticated empirical observation translated through a different but internally coherent conceptual apparatus.

2.2 Correspondences with Contemporary Oncological Science

Ayurvedic Concept	Modern Oncological Correlate	Therapeutic Implication
Ama (metabolic toxic load)	Pro-inflammatory tumour microenvironment; chronic low-grade systemic inflammation	Detoxification (Panchakarma); anti-inflammatory botanicals
Agni dysfunction	Mitochondrial dysfunction; aerobic glycolysis (Warburg effect); dysbiosis	Digestive and metabolic restoration; prebiotic and probiotic Basti
Ojas depletion	Immunosuppression; NK cell hypofunction; CD8+ T-cell exhaustion	Immunomodulatory Rasayana therapy

Ayurvedic Concept	Modern Oncological Correlate	Therapeutic Implication
Srotorodha (channel occlusion)	Lymphatic stasis; pathological angiogenesis; impaired tissue perfusion	Abhyanga; Swedana; anti-angiogenic botanicals
Dhatu Kshaya (tissue depletion)	Cancer cachexia; sarcopaenia; myelosuppression; hypoalbuminaemia	Anabolic Rasayana; nutritional support; haematopoietic herbs
Tridosha Vaishamya	Cytokine storm; systemic immune dysregulation; neuroendocrine disruption	Multi-modal doshic rebalancing through diet, herbs, and lifestyle

3. Mechanistic Evidence: Molecular and Cellular Pathways

3.1 Induction of Tumour Cell Apoptosis

Among the most robustly replicated mechanistic findings in Ayurvedic pharmacology is the capacity of several Rasayana-class compounds to restore or accelerate the apoptotic programme that malignant cells have characteristically suppressed. Withanolides - a family of C28 steroidal lactones extracted from the roots of Withania somnifera - induce concentration-dependent apoptosis in breast (MCF-7, MDA-MB-231), colon (HCT116, SW480), prostate (PC-3, LNCaP), and lung adenocarcinoma (A549) cell lines through upregulation of the pro-apoptotic mediators Bax, Bad, and cleaved caspase-3 and -9, with concurrent suppression of Bcl-2 and Bcl-xL.5,7,23,25 Withaferin A, the most extensively studied individual withanolide, additionally disrupts vimentin and annexin II filament networks, impairing the cytoskeletal remodelling that epithelial-mesenchymal transition requires.18,26

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), the principal curcuminoid of Curcuma longa, activates the intrinsic mitochondrial apoptotic pathway across more than 50 cancer cell lines via p53 stabilisation, cytochrome c release, and caspase-9/-3 cascade activation.9,27 Nimbolide, a tetranortriterpenoid limonoid from Azadirachta indica, induces reactive oxygen species (ROS)-dependent apoptosis in human cervical and pancreatic carcinoma lines while remaining substantially non-toxic to normal diploid fibroblasts at equivalent concentrations - a differential cytotoxicity profile of clear clinical relevance.12,26

3.2 Cell Cycle Disruption

Berberine, the isoquinoline alkaloid of Berberis aristata (Daruharidra), produces concentration-dependent G1/S and G2/M cell cycle arrest in hepatocellular (HepG2, Huh7) and cervical (HeLa, CaSki) carcinoma lines, mechanistically attributable to downregulation of cyclin D1, cyclin E, CDK4, and CDK6, with compensatory upregulation of the cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1).12 Acetyl-keto-beta-boswellic acid (AKBA), isolated from Boswellia serrata resin, inhibits DNA topoisomerases I and II-alpha - enzymes essential for the chromosomal decatenation that cell division requires - and has been shown to arrest glioblastoma, leukaemia, and colorectal carcinoma lines in G1 phase.13

3.3 Suppression of NF-κB and STAT3 Oncogenic Signalling

Two transcription factors with well-established roles in cancer cell survival, treatment resistance, and immune evasion - NF-κB and STAT3 - are inhibited by multiple Ayurvedic phytochemicals through distinct but complementary mechanisms. Curcumin suppresses IKKβ phosphorylation, thereby preventing IκB degradation and blocking NF-κB nuclear translocation.9,20,26,27 At nanomolar concentrations, Withaferin A targets both the NF-κB pathway (through HSP90 inhibition and IKK disruption) and STAT3 (through direct binding to its SH2 domain), producing dual oncogenic pathway suppression with a single compound.18,25,26 Ursolic acid, found in substantial concentration in the leaves of Ocimum sanctum (Tulsi), similarly inhibits JAK1/2-STAT3 phosphorylation and has demonstrated suppression of STAT3-dependent gene expression in hepatocellular carcinoma models.12,26

3.4 Anti-Angiogenic and Anti-Metastatic Activity

Curcumin suppresses tumour neovascularisation through transcriptional downregulation of VEGF-A and attenuation of VEGFR-2 autophosphorylation, effectively starving tumours of the vascular supply required for growth beyond 1–2 mm.9,27 Tinospora cordifolia alkaloidal and glycosidic constituents reduce MMP-2 and MMP-9 expression in invasive breast cancer models, attenuating the extracellular matrix degradation that metastatic dissemination requires.17,25,26 Nimbolide disrupts focal adhesion kinase (FAK) signalling in pancreatic cancer cells, impairing both migratory and invasive capacity.12,26

3.5 Immunomodulatory Mechanisms

Cancer-associated immunosuppression - encompassing depletion of natural killer (NK) cell pools, CD8+ T-cell exhaustion, regulatory T-cell expansion, and myeloid-derived suppressor cell accumulation - represents both a feature of disease progression and a major consequence of cytotoxic treatment. The Rasayana class of Ayurvedic herbs was historically prescribed precisely to reconstitute vital and immune force depleted by chronic disease, and

their contemporary pharmacological characterisation has largely validated this indication.5,10,23,25

Withania somnifera root extract enhances NK cell cytotoxic activity, restores macrophage phagocytic function suppressed by cyclophosphamide, and elevates splenic lymphocyte proliferative responses to mitogenic stimulation.5,11,23 In a landmark murine study, Davis and Kuttan reported near-complete restoration of haematopoietic progenitor populations - bone marrow cellularity, erythrocyte count, haemoglobin, and leucocyte differential - following W. somnifera supplementation in cyclophosphamide-treated animals, at a magnitude comparable to granulocyte colony-stimulating factor administration.11,23 Tinospora cordifolia activates the complement pathway, stimulates macrophage nitric oxide synthesis, and selectively upregulates Th1-type cytokines (IL-2, IFN-γ, TNF-α) while simultaneously suppressing the Th2-skewing that tumours characteristically induce.8,17,25 Emblica officinalis (Amalaki), the richest botanical source of vitamin C yet identified, modulates NF-κB-driven cytokine production, reduces circulating IL-6 and CRP, and provides substantial antioxidant buffering capacity relevant to chemotherapy-related oxidative tissue damage.10,23

3.6 Selective Cytotoxicity of Triphala

Triphala occupies a pharmacologically unusual position among Ayurvedic formulations in that it demonstrates concentration- and pH-dependent differential cytotoxicity: preferential killing of malignant cells while exerting cytoprotective antioxidant effects in normal tissue. This selectivity has been attributed to its galloyl-glucose tannin content - particularly emblicanin A and B, punicalagin, and chebulinic acid - which generate free radicals in the acidic pH environment characteristic of solid tumour microenvironments while scavenging radicals in the near-neutral pH of normal tissues.6,26 This mechanism is of particular interest in the context of radiation and chemotherapy, where collateral oxidative damage to normal tissue represents a primary source of treatment morbidity.

4. Principal Ayurvedic Herbs and Formulations in Oncological Application

4.1 Monograph Evidence Summary

Herb (Sanskrit/Binomial)	Key Phytochemicals	Documented Anti-Cancer Mechanisms	Cancer Models Studied	Strength of Evidence
Withania somnifera (Ashwagandha)	Withanolides, Withaferin A, Withanosides	Apoptosis via Bax/caspase-3; NF-κB/STAT3 inhibition; NK cell activation; myeloprotection	Breast, colon, prostate, lung, leukaemia	Preclinical: strong; Clinical: moderate (RCT data available)
Curcuma longa (Haridra/Turmeric)	Curcumin, demethoxycurcumin, bisdemethoxycurcumin	NF-κB suppression; VEGF inhibition; caspase-mediated apoptosis; STAT3 blockade	Colorectal, pancreatic, breast, head and neck, multiple myeloma	Preclinical: very strong; Clinical: moderate (bioavailability challenge)
Tinospora cordifolia (Guduchi)	Tinosporin, berberine, tinosporaside, Arabinogalactan	Macrophage activation; Th1 cytokine upregulation; anti-angiogenesis; MMP inhibition	Breast, liver, Ehrlich ascites, lymphoma	Preclinical: strong; Clinical: moderate
Emblica officinalis (Amalaki/Amla)	Emblicanin A/B, gallic acid, ellagic acid, vitamin C	Antioxidant; anti-inflammatory; radio-sensitisation; immunostimulatory	Cervical, liver, breast, skin	Preclinical: strong; Clinical: preliminary
Boswellia serrata (Shallaki)	AKBA, alpha- and beta-boswellic acids	5-LOX inhibition; topoisomerase I/II-alpha inhibition; G1 arrest; apoptosis	Glioma, leukaemia, colorectal, prostate	Preclinical: strong; Clinical: moderate (cerebral oedema RCT)
Ocimum sanctum (Tulsi)	Ursolic acid, eugenol, rosmarinic acid, luteolin	JAK/STAT3 inhibition; apoptosis; radioprotection of normal tissue	Oral, lung, skin, hepatocellular	Preclinical: moderate; Clinical: limited
Azadirachta indica (Nimba/Neem)	Nimbolide, azadirachtin, gedunin, limonoids	ROS-mediated apoptosis; FAK inhibition; hepatoprotection; NK activation	Breast, cervical, pancreatic, colon	Preclinical: strong; Clinical: limited
Semecarpus	Bhilawanols,	Anti-proliferative; pro-	Breast	Preclinical:

Herb (Sanskrit/Binomial)	Key Phytochemicals	Documented Anti-Cancer Mechanisms	Cancer Models Studied	Strength of Evidence
anacardium (Bhallataka)	anacardic acid, biflavonoids	apoptotic; anti-inflammatory; immunostimulatory	adenocarcinoma, fibrosarcoma	moderate; Clinical: case series only

Legend - Evidence strength: Very strong = multiple independent laboratories, >20 publications; Strong = consistent evidence, >10 publications; Moderate = evidence from 5–10 studies with reasonable consistency; Limited = preliminary data, <5 studies or single laboratory.

4.2 Classical Polyherbal Formulations

4.2.1 Triphala

Of all classical Ayurvedic formulations examined in oncological research, Triphala - a combination of three dried fruits, Emblica officinalis, Terminalia bellirica (Bibhitaki), and Terminalia chebula (Haritaki), in equal parts - commands the largest and most methodologically diverse evidence base. More than 50 independent peer-reviewed investigations have documented cytotoxic, pro-apoptotic, anti-metastatic, or radioprotective activity in various cancer models.6,26 Sandhya et al. reported complete regression of Dalton's lymphoma ascites in intraperitoneal murine models following oral Triphala administration, with histological confirmation of tumour destruction.6,26 Subsequent in vitro work has confirmed selective cytotoxicity against MCF-7, HCT-116, A549, and HeLa cell lines at concentrations that spare normal peripheral blood lymphocytes - a critical safety consideration in the oncological context.

Clinically, the most immediately applicable finding relates to radiation-induced oral mucositis. Peer-reviewed data from randomised controlled settings indicate that Triphala mouthwash (1% aqueous decoction, gargled for 60 seconds four times daily) significantly reduces both the peak mucositis grade on the WHO scale and the duration of severe mucositis in head and neck cancer patients undergoing curative radiotherapy.19,22,29 This finding has been replicated in independent institutions and warrants incorporation into supportive care guidelines pending larger confirmatory studies.

4.2.2 Kanchnar Guggulu

Kanchnar Guggulu is the principal classical formulation specifically indicated in Ayurvedic texts for Granthi (lymphadenopathy, benign tumours) and Gandamala (scrofulous cervical adenopathy). Its active matrix centres on guggulsterones E and Z - tetracyclic diterpenoids isolated from Commiphora mukul resin - which inhibit IKK phosphorylation, block NF-κB p65 nuclear translocation, and sensitise cancer cells to death receptor-mediated apoptosis.14 Bauhinia variegata bark extracts incorporated in the formulation contribute flavonoid-mediated anti-proliferative activity against MCF-7 and HeLa lines at IC50 values in the low microgram range.14 Clinical case series describe therapeutic benefit in thyroid adenoma, uterine myoma, and cervical lymph node enlargement secondary to haematological malignancy, though controlled trial data remain scarce.

4.2.3 Chyawanprash and Brahma Rasayana

Chyawanprash - an ancient electuary formulation with Emblica officinalis as its primary constituent, combined with 49 additional herbs, ghee, sesame oil, and honey - functions as a comprehensive haematopoietic and immunological tonic. Its documented capacity to elevate haemoglobin, restore leucocyte counts following myelosuppressive chemotherapy, and augment NK cell and macrophage activity makes it a clinically logical adjunct in the post-chemotherapy recovery phase.10,12,23,25 Brahma Rasayana, a related formulation incorporating Withania somnifera, Shatavari (Asparagus racemosus), and Tinospora cordifolia in a ghee base, has demonstrated significant radioprotective efficacy in whole-body gamma irradiation models through preservation of splenic architecture and bone marrow cellularity.12,25

5. Panchakarma Detoxification in Cancer Supportive Care

5.1 Rationale and Procedural Overview

Panchakarma is not a single procedure but a sequenced, individually calibrated detoxification and rejuvenation programme comprising five classical therapeutic actions: Vamana (induced emesis), Virechana (purgation), Basti (medicated enema), Nasya (nasal administration of medicated oils), and Raktamokshana (phlebotomy or leech therapy). In the oncological setting, Panchakarma is neither proposed as primary anti-tumour treatment nor employed during active chemotherapy or radiotherapy cycles. Its place is as a preparatory, inter-cycle, or post-treatment supportive intervention, aimed at reducing Ama burden, normalising doshic imbalance, stimulating eliminatory and detoxificatory physiology, and restoring the functional capacity of Srotas disrupted by both disease and treatment.3,21,24

In practice, the procedures most commonly integrated into cancer supportive care programmes are Virechana (hepatic and gastrointestinal detoxification, particularly relevant following hepatotoxic chemotherapy) and Basti (colonically administered preparations utilising medicated oils, decoctions, and milk bases). Both are preceded by

the mandatory preparatory sequence of Snehana (internal and external oleation with medicated ghee and oil, respectively) and Swedana (supervised sudation through steam or herbal poultice application), which mobilise tissue-bound Ama into the gastrointestinal lumen for subsequent elimination.

5.2 Clinical and Mechanistic Evidence

A prospective observational cohort study evaluated a structured Panchakarma protocol - comprising Snehana, Sarvanga Abhyanga (full-body oil massage), Bashpa Swedana (steam sudation), and Virechana - in patients with solid tumours receiving concurrent conventional treatment.16 Statistically significant improvements were documented in FACIT-F fatigue scores, Karnofsky Performance Status, haemoglobin concentration, total leucocyte count, and neutrophil absolute count at 30-day follow-up relative to baseline. Erythrocyte sedimentation rate and serum CRP - markers of systemic inflammation - were both significantly reduced.16

The proposed mechanistic basis for these findings draws on several converging processes. Repeated Abhyanga (warm sesame oil massage) activates cutaneous lymphatic drainage, reduces plasma cortisol concentration, and elevates plasma levels of calcitonin gene-related peptide - a neuromodulatory peptide with immunostimulatory properties. Internal Snehapana with medicated ghee facilitates the solubilisation and gastrointestinal excretion of lipophilic xenobiotics and inflammatory lipid mediators. Basti preparations containing Withania somnifera, Shatavari, and Bala (Sida cordifolia) deliver anabolic and immunomodulatory phytochemicals directly to the colonic mucosa with high local bioavailability, with systemic absorption via portal circulation.

6. Clinical Evidence: Key Symptom Domains

6.1 Cancer-Related Fatigue

Cancer-related fatigue (CRF) is the most prevalent and functionally disabling symptom across all cancer types and treatment modalities, affecting 60–80% of patients receiving systemic therapy. Unlike physiological fatigue, CRF does not resolve with rest, is only partially responsive to erythropoiesis-stimulating agents, and persists for months to years following treatment completion in a substantial proportion of survivors.2,28 A randomised, double-blind, placebo-controlled pilot trial enrolled 100 women with stage II–III breast cancer receiving adjuvant chemotherapy and administered Withania somnifera standardised root extract (500 mg twice daily) or matched placebo for the duration of chemotherapy.7,23,25 The treatment group demonstrated significantly lower scores on the Brief Fatigue Inventory at weeks 4 and 8, and significantly higher FACT-G total quality-of-life scores at completion, with no serious adverse events attributable to the intervention.7,23,25 The proposed mechanism involves withanolide-mediated modulation of hypothalamic-pituitary-adrenal axis reactivity, mitochondrial biogenesis upregulation, and suppression of pro-inflammatory cytokine cascades (IL-6, TNF-α) that drive CRF pathophysiology.5,7,23,25

6.2 Chemotherapy-Induced Nausea and Vomiting

The antiemetic properties of Zingiber officinale (Shunthi in Ayurvedic classification) are among the most consistently demonstrated therapeutic effects of any botanical intervention in clinical oncology. Bioactive gingerols and shogaols inhibit 5-HT3 receptors on vagal afferents in the gastrointestinal tract - the same molecular target as ondansetron and related antiemetics - and additionally modulate substance P/neurokinin-1 receptor signalling and cannabinoid CB1/CB2 receptor activity through their cyclooxygenase-2 inhibitory properties.8,22 A pivotal randomised trial involving 576 cancer patients receiving emetogenic cisplatin-based or anthracycline-based regimens demonstrated that ginger supplementation at 0.5 g and 1.0 g daily doses produced statistically significant and clinically meaningful reductions in acute nausea severity on a validated 7-point Likert scale when added to standard 5-HT3 antagonist prophylaxis.8,22

6.3 Radiation-Induced Oral Mucositis

Radiation-induced oral mucositis (RIOM) develops in virtually all patients receiving curative-intent radiotherapy for head and neck cancers, with approximately 85% experiencing WHO grade 3–4 mucositis that causes severe pain, odynophagia, and treatment breaks that may compromise oncological outcomes. Current prophylactic strategies - basic oral hygiene, topical anaesthetics, and glutamine supplementation - provide incomplete protection.19,22,29 Triphala mouthwash at a 1% aqueous concentration was evaluated in a randomised controlled trial of 60 head and neck cancer patients receiving definitive radiotherapy (66 Gy, 6.5 weeks), where it produced statistically significant reductions in peak mucositis grade (mean WHO grade: 1.6 vs. 2.8, $p < 0.001$), total mucositis duration (12 days vs. 21 days), VAS pain score, and analgesic consumption, relative to chlorhexidine mouthwash control.19,22 No adverse reactions were reported. The mechanism is attributed to synergistic anti-inflammatory, antioxidant, and mucosal epithelial regenerative activity of the constituent tannins and polyphenols, particularly emblicanin, punicalagin, and chebulic acid.

6.4 Haematological Recovery and Myeloprotection

Chemotherapy-induced bone marrow suppression - manifest as neutropenia, thrombocytopenia, and anaemia - is the primary dose-limiting factor in curative systemic therapy, responsible for treatment delays, dose reductions, and infection-related mortality. An open-label prospective study administered Tinospora cordifolia standardised aqueous extract (500 mg three times daily) to 60 patients

receiving carboplatin-paclitaxel or cisplatin-fluorouracil significantly fewer grade 3/4 neutropenic episodes (13% vs. 37%), reduced G-CSF administration requirements, and faster absolute neutrophil count recovery to >1.0 × 10^9/L, compared to standard care control.17,23,25 Punarnava Mandur (an iron-mineral complex with Boerhavia diffusa as the principal herb), when combined regimens.8,17,23,25 The treatment group experienced with Ashwagandha supplementation, has demonstrated improvement in haemoglobin, serum ferritin, and transferrin saturation in cancer-associated anaemia through both haematopoietic stimulation and enhanced iron utilisation efficiency.10,23,25

6.5 Consolidated Evidence Table

Symptom Domain	Principal Intervention(s)	Study Design	Key Endpoint(s)	Outcome	Evidence Grade
Cancer-related fatigue	Withania somnifera 500 mg BD	Randomised controlled trial (n=100)	BFI score; FACT-G	Significant improvement both scales	B - single RCT, pilot
CINV (acute)	Zingiber officinale 0.5–1.0 g/day	RCT (n=576)	VAS nausea severity	Significant reduction vs. placebo add-on	A - multi-site RCT
Radiation oral mucositis	Triphala mouthwash 1%	RCT (n=60)	WHO mucositis grade; VAS pain	Significant grade and duration reduction	B - single-centre RCT
Neutropenia/myelosuppression	Tinospora cordifolia	Open-label prospective	Grade 3/4 events; ANC nadir	Fewer severe events; faster recovery	C - open-label only
Anaemia	Punarnava Mandur + Ashwagandha	Prospective observational	Hb, serum ferritin, TSAT	Significant Hb and iron store improvement	C - observational
CIPN (peripheral neuropathy)	Bacopa monnieri; Ashwagandha	Pilot observational	CIPN assessment tool	Symptom score improvement	D - preliminary
Hepatotoxicity (chemo)	Phyllanthus niruri	Small clinical series	ALT, AST, bilirubin normalisation	Improved LFTs in majority	D - case series
Global quality of life	Multimodal Rasayana protocols	Prospective cohort	EORTC QLQ-C30, FACT-G	General improvement reported	C - observational

Evidence grades follow SORT (Strength of Recommendation Taxonomy): A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice; D = preliminary/pilot data only.

7. Ayurvedic Dietary and Lifestyle Prescriptions in Oncological Practice

A fundamental distinction between Ayurvedic therapeutics and the contemporary pharmacological model is that dietary and lifestyle modifications (Ahara and Vihara) are considered first-order therapeutic interventions rather than adjunctive measures. The classical doctrine of Pathya-Apathya (beneficial and contraindicated food-lifestyle combinations) provides a systematic oncological nutritional framework with a number of notable convergences with modern nutritional oncology evidence.3,28

The Ayurvedic dietary prescription for patients with active malignancy or those undergoing cytotoxic treatment centres on foods that kindle rather than suppress Agni: warm, freshly prepared, moderately spiced, and easily digestible preparations are preferred over cold, heavy, processed, or stale foods. This principle is operationally concordant with evidence-based dietetic guidance for managing dysgeusia, mucositis-related dysphagia, and chemotherapy-induced gastroparesis. The prescription to incorporate Agni-stimulating spices - turmeric, ginger, black pepper, and cumin - in daily cooking simultaneously provides anti-inflammatory and immunomodulatory phytochemical delivery through the diet.3,9,27,28 Notably, the classical practice of combining

turmeric with black pepper in cooking was pharmacologically validated through the demonstration that piperine, the active alkaloid of Piper nigrum, enhances curcumin oral bioavailability by approximately 2000% through inhibition of CYP3A4-mediated first-pass metabolism and P-glycoprotein efflux.9,27

The Ayurvedic lifestyle framework for oncology patients - regularised sleep-wake cycles (Dinacharya), gentle yoga and controlled pranayama as tolerated by performance status, meditation-based stress reduction, and communal social engagement - aligns closely with the psychoneuroimmunological evidence base for lifestyle oncology interventions. ASCO guidelines and the World Cancer Research Fund both recommend structured physical activity, stress reduction, and avoidance of tobacco and alcohol for cancer survivors - recommendations that the classical Ayurvedic framework had institutionalised millennia earlier.2,3,28

8. Safety, Contraindications, and Drug-Herb Interactions

8.1 General Safety Considerations

When prescribed and prepared appropriately, by practitioners trained in classical Ayurvedic pharmacognosy and aware of the specific vulnerabilities of oncology patients, the botanical Rasayana agents reviewed in this paper have favourable safety profiles documented across extensive population use and, increasingly, formal clinical safety evaluation.15,22,24 However, the oncology patient population presents specific heightened risks that must inform clinical decision-making. Impaired hepatic and renal function secondary to chemotherapy alters drug-herb metabolic kinetics. Thrombocytopenia increases bleeding risk from antiplatelet botanical constituents. Neutropenia raises the possibility, though unconfirmed, of immunostimulatory herbs precipitating inflammatory flares in immunologically vulnerable patients.

8.2 Pharmacokinetic Drug-Herb Interactions

Herb / Formulation	Implicated Drug Class	Mechanism of Interaction	Clinical Management Recommendation
Withania somnifera (Ashwagandha)	Thyroid hormone therapy; immunosuppressants	Thyroid-stimulating activity; immune activation	Monitor TFTs; exercise caution in transplant patients on calcineurin inhibitors
Curcumin (high-dose supplements)	Warfarin; antiplatelet agents; some taxanes	CYP2C9/3A4 inhibition; COX-1-mediated antiplatelet activity	Avoid high-dose supplements during anticoagulation; monitor INR; consider dose separation
Triphala	Oral iron supplements; broad range of oral drugs	Tannin-mediated chelation of iron and binding of drug molecules	Administer minimum 2 hours apart from other oral medications and iron supplements
Tinospora cordifolia (Guduchi)	Immunosuppressants (tacrolimus, ciclosporin)	Complement activation; macrophage stimulation could counter calcineurin inhibitor effects	Avoid use in organ transplant patients without specialist supervision
Zingiber officinale at high dose	Anticoagulants; sulphonylureas	6-shogaol-mediated COX-1 inhibition; insulin sensitisation	Limit supplemental dose to <2 g/day during anticoagulant therapy; monitor fasting glucose
Boswellia serrata	NSAIDs; 5-fluorouracil	Additive 5-LOX inhibition; possible CYP3A4 interaction	Monitor GI tolerability; notify prescribing oncologist before concurrent use

The issue of heavy metal-containing classical preparations (Rasa Shastra) warrants explicit mention. Formulations such as Makaradhwaja, Swarna Bhasma, and certain Kalpas incorporate mercury sulphide, gold, silver, and iron ores that have been processed through rigorous classical purification procedures (Shodhana, Marana) theoretically rendering them safe and therapeutically active.15,22,24 However, the consistency of Shodhana across manufacturing facilities - ranging from classical hand-processed artisanal production to large-scale industrial manufacture - varies enormously, and heavy metal bioavailability data for commercially available preparations are generally lacking. In the context of concurrent platinum, taxane, or anthracycline chemotherapy with their inherent renal and hepatic toxicity profiles, unverified heavy metal-containing preparations should be categorically avoided until robust pharmacokinetic safety data in oncology populations are

available.

9. Limitations of Current Evidence and Outstanding Methodological Challenges

The foregoing review, while highlighting a substantial and growing evidence base, must be read in awareness of persistent methodological constraints that limit the confidence with which clinical recommendations can be drawn:

- Sample size and statistical power: A majority of clinical studies, including the RCTs cited, were designed as feasibility or pilot investigations. Effect size estimates derived from small trials are subject to substantial variability, and the published estimates likely reflect publication bias towards positive findings. Adequately powered confirmatory trials remain the single greatest need.
- Preparation heterogeneity and lack of standardisation: Herbal preparations described under identical classical names may differ substantially in phytochemical composition based on plant origin geography, harvest season and maturity, drying method, extracting solvent, and manufacturer quality systems. Absence of standardised, certificate-of-analysis-supported, pharmacopoeially defined preparations makes study replication across sites methodologically impossible and cross-study comparison unreliable.
- Bioavailability constraints: Curcumin, despite its extraordinary in vitro potency, achieves plasma concentrations of less than 10 ng/mL following conventional oral dosing - concentrations orders of magnitude below those required to produce the NF-κB inhibition and apoptotic induction documented in cell culture systems. Novel delivery platforms (phospholipid complexes, solid lipid nanoparticles, self-emulsifying formulations) substantially improve systemic exposure but have not been subjected to large-scale clinical evaluation.
- Mechanistic reductionism versus holistic complexity: Ayurvedic formulations are not isolated compounds but complex botanical matrices in which hundreds of phytochemicals interact synergistically. The pharmacodynamic activity of Triphala, for example, cannot be reduced to the activity of any single constituent. Conventional pharmacological methodology, designed for single-molecule characterisation, is ill-suited to this complexity. Systems pharmacology, network pharmacology, and metabolomics offer more appropriate analytical frameworks.
- Absence of pharmacokinetic data in co-administration: Despite the widespread use of Ayurvedic preparations alongside chemotherapy in South and Southeast Asia, formal pharmacokinetic drug-herb interaction studies in oncology patient populations are almost entirely lacking. The theoretical and observed interaction risks described in Section 8 require prospective clinical investigation before definitive safety guidance can be issued.
- Investigator conflict of interest and publication bias: A disproportionate number of clinical publications originate from institutional contexts with inherent interests in demonstrating Ayurvedic efficacy. Independent replication by non-affiliated groups is necessary to establish reproducibility and eliminate confirmation bias.

10. Future Research Priorities and the Path to Integration

10.1 Large-Scale Randomised Controlled Trials

The field's most urgent need is adequately powered, multi-centre, double-blind randomised controlled trials testing well-characterised, standardised Ayurvedic preparations in clearly defined oncological populations with validated primary endpoints. Triphala mouthwash for RIOM prevention, Withania somnifera for CRF in breast and colorectal cancer, Tinospora cordifolia for myeloprotection in platinum-based regimens, and ginger for CINV prophylaxis - each represents a clinical application with sufficient preliminary evidence to justify a phase II/III trial investment29

Trial design must grapple with the inherent tension between Ayurvedic clinical practice - which prescribes individualised, dynamically adjusted regimens - and the methodological requirement for uniform intervention arms. Adaptive trial designs, pragmatic RCTs with structured flexibility arms, and n-of-1 crossover designs offer potential methodological solutions. Stratification by Prakriti (Ayurvedic constitutional type) as a trial variable - now technically feasible through validated psychometric instruments - could identify subpopulations with differential treatment response, generating actionable precision medicine data from an ancient framework.30-32

10.2 Translational and Pharmacological Research

Pharmacokinetic studies in cancer patients receiving concurrent chemotherapy are a prerequisite for safe clinical integration and represent a gap that academic pharmacology institutions are uniquely positioned to address. Systems pharmacology - combining molecular docking, multi-target network analysis, and transcriptomic profiling - should be applied to priority classical formulations to generate comprehensive mechanism maps that can inform rational dose optimisation and interaction risk prediction.33-35 Nanotechnology-enabled delivery systems for curcumin and AKBA are approaching clinical readiness and should be prioritised for phase I oncology dose-finding studies. 36-38

10.3 Structural Integration into Oncology Practice

investment beyond clinical trials. Integrative oncology units - modelled on established programmes at the M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Osher Centre for Integrative Medicine - should be developed within India's comprehensive cancer centre network, staffed by Ayurvedic practitioners with postgraduate oncology training working alongside medical oncologists, radiation oncologists, and palliative care physicians.39-43 Clinical practice guidelines for the use of Ayurvedic interventions in oncology supportive care - analogous to ASCO or ESMO supportive care guidelines - should be developed through structured expert consensus processes informed by systematic reviews. These guidelines should frankly acknowledge evidence quality, clearly distinguish indications with moderate or stronger evidence from those with only preliminary support, and provide explicit safety contraindications.44-46

11. Conclusion

A candid reading of the available evidence leads to the following conclusions. First, Ayurveda is not an empirically vacuous folk tradition: its classical descriptions of neoplastic disease pathogenesis demonstrate genuine biological insight, and its pharmacological armamentarium contains compounds whose mechanistic properties are among the most extensively characterised in natural product oncology.3,4,9,21,26,27

Second, several Ayurvedic interventions - principally

Sustainable clinical integration requires structural Withania somnifera, Tinospora cordifolia, Emblica officinalis, Triphala, and ginger - have generated clinical evidence for meaningful benefit in specific, well-defined oncological supportive care domains: fatigue, CINV, oral mucositis, and haematological recovery. While no intervention has yet achieved grade A evidence status, the totality of the evidence crosses a threshold that justifies their incorporation into structured integrative care programmes within appropriately monitored clinical settings.5,6,7,8,10,17,19,22,23,25,28,29

Third, the evidence base is structurally limited by preparation heterogeneity, insufficient sample sizes, limited pharmacokinetic data, and a relative absence of independent replication. These are solvable problems; solving them requires sustained, adequately funded, methodologically rigorous research commitment from academic oncology institutions, government health agencies, and the Ayurvedic pharmaceutical sector.2,21,24,28

The clinical imperative, ultimately, is not ideological. Patients with cancer suffer profoundly - from their disease and from the treatments they endure. Where evidence-supported interventions from any tradition can meaningfully reduce that suffering, the ethical obligation of medicine is to study them rigorously and, where warranted, deploy them responsibly. Ayurveda, at this moment, occupies an evidence status that makes continued exclusion from integrative oncology care neither scientifically defensible nor ethically justifiable.

References

1. Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Ann Pharmacother. 2005;39(7–8):1258–63.
2. Gandhi MY, Prasad SB, Kumar V, Soni H, Rawat H, Mishra SK, Grewal J, Singh S, Charde V, Gupta A, Jha SK. Quantification of phytochemicals and metal ions as well as the determination of volatile compounds, antioxidant, antimicrobial and antacid activities of the Mimosa pudica L. leaf: Exploration of neglected and under-utilized part. Chemistry & biodiversity. 2023 Oct;20(10):e202301049.
3. Shamim, Ali S, Ali T, Sharma H, Kishor BN, Jha SK. Recent advances in monodisperse gold nanoparticle delivery, synthesis, and emerging applications in cancer therapy. Plasmonics. 2025 Sep;20(9):7121-41.
4. Gandhi Y, Kumar V, Singh G, Prasad SB, Mishra SK, Soni H, Rawat H, Singh S, Charde V, Gupta A, Dhanjal DS. Chemoprofiling and medicinal potential of underutilized leaves of Cyperus scariosus. Scientific Reports. 2024 Mar 27;14(1):7263.
5. Jha SK, Islam M, Kumar R, Rana L, Saifi MA, Ali S, Alam N. Evaluation of Vernonia amygdalina del. containing phyto constituents a medicinal plant compound as new potential inhibitors of Monkey pox virus using molecular docking analysis. World J Adv Res Rev. 2023;17(1):1112-22.
6. Singh A, Jha SK, Dwivedi PC, Srivastava U, Pal A. Revolutionizing healthcare: Integrating electronics, AI, traditional, and conventional methods. World J Adv Res Rev. 2024;23:2426-34.
7. Lohiya GV. Conjunctivitis in unusual populations: A review of rare cases and challenges in diagnosis and management. World Journal of Advanced Research and Reviews. 2023 Sep 29.
8. Lohiya GV. Conjunctivitis in unusual populations: A review of rare cases and challenges in diagnosis and management. World Journal of Advanced Research and Reviews. 2023 Sep 29.
9. Doshi R, Lohiya G. Synthesis, in-silico design and spectral characterization, elucidation of Cannabis sativa L. cannabaceae containing phytoconstitutents demonstrating novel therapeutic efficacy against epilepsy.
10. Jha SK, Mishra AK, Kumar V, Dane G, Kumari S, Charde V, Saddam M, Jagtap C, Chuhan S, Chaturvedi SK, Narasimhaji CV. Ecological and

Behavioral Impacts of COVID-19 on Human Existence and potential preventive measures through traditional and alternative medicine–A Narrative review. Pharmacological Research-Natural Products. 2024 Jun 1;3:100042.
11. Sonkar V, Jha SK, Tiwari S, Akarsh A, Priya S, Sharan P, Sharan A. Characterization and explanation of the soil fertility state of Sakaldiha block in the Chandauli District of Uttar Pradesh's industrial area. World J Adv Res Rev. 2023;18:063-72.
12. Singh NK, Sengar AS, Jha SK. A review of Ayurvedic measures for preventing COVID-19 and promoting health during pregnancy. Journal of Indian System of Medicine. 2024 Apr 1;12(2):61-5.
13. Chauhan S, Jha SK, Tamta A, Sharma V, Kumar C, Lohiya G, Gadgul A, Satpute K, Chalmale N, Chauhan P, Chaturvedi SK. Descriptive analytical study based on profiling, morphological, pomological and pharmacological traits to identify the genotypes of the promising mango Mangifera indica L. World J Adv Res Rev. 2023;19:1544-53.
14. Khan R, Maheshwari D, Chauhan S, Lohiya GV, Kumar C, Antil I, Sharma S, Garg Y, Chauhan P, Jha SK. Exploring the potential therapeutic value of Solanum lycopersicum L. phytoconstituents for Parkinson's disease through molecular docking analysis. World J Adv Res Rev. 2023;20:488-501.
15. Jha SK, Singh N, Shanker OR, Antil I, Baghel JS, Huddar V, Tripathi R. A review on integrative approaches in oncology: bridging ayurvedic medicine and modern cancer therapeutics. Frontiers in Natural Products. 2025 Aug 22;4:1635197.
16. Tamta A, Jha SK. Screening of Germplasms and Population Dynamics of Major Insect Pests of Spring Green Gram Vigna radiata (Linn.) (Doctoral dissertation, Doctoral Dissertation, Doctoral Dissertation, GB Pant University of Agriculture and Technology, Pantnagar-263145 (Uttarakhand)).
17. Mehta V, Zargar AA, Attri P, Jha SK. Bagging the role of herbal drugs in the management of cervical cancer. Ayush Journal of Integrative Oncology. 2025 Jan 1;2(1):35-43.
18. Trivedi LM, Saxena S, Sharma S, Beniwal M, Jha SK, Rao AK, Khan MR. Characterization, profiling, and molecular docking analysis of phytochemicals derived from Daucus carota for evaluating their potential role in cardiovascular disease (CVD) assessment. World J Adv Res Rev. 2023;20:159-75.
19. Patel S, Singh S, Gupta AK, Dalimbe AY, Muthoju SM, Pawar AR, Jha SK, Gupta AJ. Ayurveda and common Indian spices: A natural alternative for cancer therapy. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):91-102.
20. Jha SK, Gupta A, Huddar VG. Botanical breakthroughs: The growing impact of plant-derived compounds in cancer treatment. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):62-7.
21. Kumar R, Verma H, Ali M, Midha T, Kumar D, Jha SK. Review of mitigating cancer risk through Ayurvedic practices: A holistic approach to combating sedentarism. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):86-90.
22. Sharma A, Jha SK, Huddar VG. Integrative role of Ayurvedic phytochemicals in cancer treatment: Targeting signaling pathways, boosting chemosensitivity, and utilizing traditional therapeutics. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):77-85.
23. Jha SK, Charde V, Kumar V, Narasimhaji CV. Vitiligo treatment with natural bioactive: A narrative review. The Natural Products Journal. 2026 Mar;16(3):e22103155337960.
24. Chawla S, Gupta R, Jha SK, Kashid S, Jha KT. Stereoisomerism in Chemistry and Drug Development: Optical, Geometrical, and Conformational Isomers. Medicinal Chemistry (Shariqah (United Arab Emirates)). 2025.
25. Shrivastav S, Tyagi R, Singh M, Jha S. The effectiveness of curcumin on dysmenorrhea. International Journal of Medical Sciences and Pharma Research. 2022 Dec 15;8(4):8-12.
26. Gupta AJ, Huddar VG, Jha SK, Soni U. Traditional wisdom in modern oncology: Ayurvedic pain relief and supportive care. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):178-87.
27. Chauhan S, Jha SK, Huddar VG, Ahlawat A, Sharma S, Tripathi A, Khurana B, Antil I, Soni U. Targeting cancer at the molecular level: A biochemical and medicinal chemistry approach. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):169-77.
28. Antil I, Bangarwa S, Jha SK, Gupta AJ, Soni U, Huddar VG, Tripathi A, Sharma S. Exploring the chemopreventive and anticancer effects of green tea. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):158-68.
29. Attri P, Zargar AA, Mehta V, Mushtaq SU, Jha SK, Soni U. Genetic basis of cancer: Harnessing natural remedies for therapeutic potential. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):188-94.
30. Zargar AA, Mehta V, Gupta R, Bhandari K, Sharma MC, Balaji P, Jha SK. Incretin hormones: Mechanisms, therapeutic implications, and future directions in glucose regulation and diabetes management. Curr Proteom. 2025 Apr 1;22:100014.
31. Dhiman S, Thakur N, Dwivedi PC, Pande P, Jha SK, Lohiya GV. Phytochemicals: investigating bioactive compounds for antifungal uses and quality issues in functional foods and therapeutics.
32. Sandrepogu J, Khandelwal P, Tiwari SK, Jha SK, Chauhan S, Sharma H, Goel P. A holistic paradigm for cancer care: Merging Ayurveda with contemporary oncology. Ayush Journal of Integrative

Oncology. 2025 Oct 1;2(4):254-61.
chemotherapy: Exploring the potential of phytomedicine in oncology. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):133-45.
34. Ahlawat A, Chauhan S, Antil I, Jha SK, Huddar VG. Examining the impact of the microbiome on cancer immunotherapy outcomes: A review. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):118-24.
35. Shamim PT, Khatri N, Yadav AK, Mishra B, Khan MR, Behera SK, Jha SK. Role of human chorionic gonadotropin in frozen-thawed embryo transfer cycles for secretory transformation: a narrative. Eur Chem Bull. 2023;12(8):5477-93.
36. Sharma H, Mahto RR, Jha SK, Chauhan S, Khandelwal P, Tiwari SK. Rasayana-Based Adjuvant Strategies in Cancer Care: An Ayurvedic–Oncologic Perspective. Iranian Journal of Blood and Cancer. 2025 Feb 30;17(4):35-68.
37. Raj H, Jha SK, Negi M, Khandelwal P, Chauhan S, Sharma H, Goel P, Tiwari SK. Integrative oncology: A comprehensive comparative analysis of herbal and allopathic medicine in cancer treatment. Current Pharmaceutical Research (CPR). 2025;1:427-5.
38. Kumar C, Chauhan P, Chauhan S, Jha SK, Lohiya G. Phyto-Pharmacognostic Experimental Study of Epimedium Sagittatum and Gloriosa Superba L. for the Treatment of Hypogonadism. Int J Innov Sci Res Technol. 2023;8(6):254-60.
39. Raj H, Sharma S, Tripathi A, Huddar VG, Jha SK. Herbal medicine in cancer therapy: A comprehensive review of phytoconstituents, mechanisms, and clinical applications. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):146-57.
40. Antil I, Jha SK, Negi M, Sharma H, Tiwari SK. Baicalein from Scutellaria baicalensis as natural therapeutic agent for glioblastoma. Current Pharmaceutical Research (CPR). 2025;1:411-26.
41. Mandal P, Kumar J, Bora D, Hashmi SA, Tiwari M, Gupta R, Behera AK, Amoli M, Singh J, Jha SK. Literature review on forensic implications of illicit drug metabolism: A medicinal chemistry perspective. Journal of Forensic and Legal Medicine. 2026 Apr 24:103158.
42. Bansal KS, Mahto RR, Soni H, Tiwari SK, Goel P, Sharma H, Vishwakarma N, Jha SK, Chauhan S, Khandelwal P. Ayurveda in Renal Cell Carcinoma: A
33. Sharma S, Yadav C, Chawla S, Jha SK. Beyond Narrative Review of Supportive Care During Targeted Therapy and Immunotherapy.
43. Bansal KS, Mahto RR, Soni H, Tiwari SK, Goel P, Sharma H, Vishwakarma N, Jha SK, Chauhan S, Khandelwal P. Ayurveda in Renal Cell Carcinoma: A Narrative Review of Supportive Care During Targeted Therapy and Immunotherapy.
44. Mahto RR, Bansal KS, Soni H, Tiwari SK, Sandrepogu J, Bhatted SK, Jha SK, Sharma H, Khandelwal P. Efficacy of Vidangadi Loha and Phalatrikadi Ghanavati with and without the prior administration of Virechana Karma in Madhumeha (Obese Diabetic): A Randomised Controlled Trial.
45. . Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161–8.
46. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005;1056:206–17.

Conflict of Interest Statement

All authors declare that they have no financial, personal, or professional conflicts of interest that could have influenced the conduct, interpretation, or reporting of this review.

Author Contributions

Conceptualisation and design: [Dr. Sonam Chauhan]. Literature search and data extraction: [Dr. Sonam Chauhan, Dr. Prachi Khandelwal]. Critical appraisal of included evidence: [All authors]. Writing - original draft preparation: [Dr. Sanjay Tiwari, Dr. Himani Sharma]. Writing - review and editing: [All authors]. Supervision and final approval: [Dr. Prachi]. All named authors have read and approved the final manuscript as submitted.

Funding Declaration

This review received no specific financial support from any public, commercial, or not-for-profit funding body.

Ethical Statement

This is a narrative review article based entirely on publicly available peer-reviewed literature and classical Ayurvedic texts. No original primary data involving human subjects or animals were generated in the course of this work. Formal ethical approval was therefore not required.